• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Evolent Health Inc (Amendment)

    2/13/24 5:04:35 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary
    Get the next $EVH alert in real time by email
    SC 13G/A 1 tv0889-evolenthealthincclass.htm SCHEDULE 13G/A evolenthealthincclassa

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  Evolent Health Inc Class A

    Title of Class of Securities:  Common Stock

    CUSIP Number:  30050B101

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  30050B101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    202,571

    7.  SOLE DISPOSITIVE POWER

    10,499,222

    8.  SHARED DISPOSITIVE POWER

    322,109

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,821,331

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.41%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Evolent Health Inc Class A

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    800 North Glebe Road, Suite 500
    Arlington, VA 22203

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    30050B101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $EVH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVH

    DatePrice TargetRatingAnalyst
    1/10/2025$15.00Buy
    Needham
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    4/22/2024$40.00Buy
    Citigroup
    3/1/2024$45.00Outperform
    Oppenheimer
    1/3/2024$39.00Overweight
    Barclays
    More analyst ratings

    $EVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Shams Aammaad covered exercise/tax liability with 2,567 shares, decreasing direct ownership by 3% to 72,899 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    8/5/25 4:11:35 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Chief Executive Officer Blackley Seth was granted 67,150 shares, increasing direct ownership by 9% to 829,367 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    7/3/25 7:12:25 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    General Counsel Weinberg Jonathan was granted 23,394 shares, increasing direct ownership by 10% to 254,179 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    7/3/25 7:10:27 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolent Announces Second Quarter 2025 Results

    WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

    8/7/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    NYSE Content Advisory: Pre-market update + Wall Street anticipates Fed's next move

    NEW YORK, July 29, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on July 29th Stocks are fractionally higher Tuesday morning following another record close on Monday for the S&P 500, though the large-cap index only saw a slight gain during yesterday's session.More than 150 companies will report earnings this week. The week will be headlined by Microsoft, Meta, Amazon, and Apple, which will release quarterly figures and guidance in the coming days.The

    7/29/25 8:55:00 AM ET
    $EVH
    $ICE
    Other Consumer Services
    Consumer Discretionary
    Investment Bankers/Brokers/Service
    Finance

    Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    7/14/25 8:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Evolent Health with a new price target

    Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00

    1/10/25 7:49:47 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    BTIG Research reiterated coverage on Evolent Health with a new price target

    BTIG Research reiterated coverage of Evolent Health with a rating of Buy and set a new price target of $29.00 from $36.00 previously

    12/3/24 7:52:53 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Health downgraded by Stephens with a new price target

    Stephens downgraded Evolent Health from Overweight to Equal-Weight and set a new price target of $16.00 from $38.00 previously

    11/8/24 7:50:07 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Leadership Updates

    Live Leadership Updates

    View All

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Other Consumer Services

    Define Ventures Appoints Carolyn Magill as Venture Partner

    The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

    3/11/25 5:30:00 AM ET
    $EVH
    $HIMS
    $LVGO
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

    Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON, Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. Dr. Nguyen joined Evolent as Chief Clinical Officer in July 2024 after serving as clinical lead for population health at Google. Among other previous roles, he has been Chief Medical Officer at Blue Cross North Carolina, Deputy Associate Director of Policy and Strategy at the Centers for Disease Control and Prevention, and Senior Advisor at the Centers for Me

    12/18/24 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/7/24 7:47:40 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    7/10/24 10:10:34 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Financials

    Live finance-specific insights

    View All

    Evolent Announces Second Quarter 2025 Results

    WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

    8/7/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    7/14/25 8:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent reiterates Q2 and full year guidance for Adjusted EBITDA

    Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M. John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thi

    6/20/25 6:30:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/14/25 3:07:26 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    SEC Form 10-Q filed by Evolent Health Inc

    10-Q - Evolent Health, Inc. (0001628908) (Filer)

    8/11/25 6:27:45 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Health Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Evolent Health, Inc. (0001628908) (Filer)

    8/7/25 4:15:43 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:20:54 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:18:12 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Jelinek Richard M bought $273,750 worth of shares (30,000 units at $9.12) (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:16:20 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary